 Eric Lavonas
Concepts (305)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Snake Bites | 28 | 2023 | 54 | 10.500 |
Why?
| | Cardiopulmonary Resuscitation | 29 | 2023 | 220 | 7.410 |
Why?
| | Antivenins | 24 | 2019 | 56 | 7.190 |
Why?
| | Agkistrodon | 14 | 2019 | 19 | 6.540 |
Why?
| | Heart Arrest | 15 | 2023 | 289 | 4.720 |
Why?
| | Immunoglobulin Fab Fragments | 11 | 2019 | 69 | 3.890 |
Why?
| | Crotalid Venoms | 8 | 2019 | 31 | 2.990 |
Why?
| | Out-of-Hospital Cardiac Arrest | 11 | 2023 | 78 | 1.850 |
Why?
| | Emergency Medical Services | 18 | 2023 | 587 | 1.840 |
Why?
| | Viperidae | 5 | 2013 | 11 | 1.720 |
Why?
| | Immunoglobulin Fragments | 5 | 2013 | 15 | 1.570 |
Why?
| | Cardiology Service, Hospital | 5 | 2020 | 28 | 1.440 |
Why?
| | Cardiology | 6 | 2020 | 259 | 1.280 |
Why?
| | Upper Extremity | 2 | 2018 | 85 | 1.130 |
Why?
| | Emergency Service, Hospital | 13 | 2020 | 1811 | 1.060 |
Why?
| | Lower Extremity | 2 | 2018 | 337 | 0.940 |
Why?
| | American Heart Association | 10 | 2023 | 264 | 0.860 |
Why?
| | Drug Overdose | 6 | 2020 | 293 | 0.860 |
Why?
| | Poison Control Centers | 5 | 2016 | 84 | 0.840 |
Why?
| | Analgesics, Non-Narcotic | 4 | 2017 | 117 | 0.840 |
Why?
| | Poisoning | 4 | 2016 | 110 | 0.820 |
Why?
| | Acetaminophen | 5 | 2017 | 237 | 0.810 |
Why?
| | Humans | 87 | 2023 | 115039 | 0.800 |
Why?
| | Analgesics, Opioid | 5 | 2021 | 774 | 0.790 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2018 | 299 | 0.760 |
Why?
| | Agranulocytosis | 2 | 2012 | 31 | 0.750 |
Why?
| | Levamisole | 2 | 2012 | 20 | 0.750 |
Why?
| | Recovery of Function | 4 | 2019 | 575 | 0.740 |
Why?
| | Consensus | 15 | 2023 | 534 | 0.730 |
Why?
| | Buprenorphine | 2 | 2014 | 134 | 0.710 |
Why?
| | Nonprescription Drugs | 2 | 2011 | 68 | 0.670 |
Why?
| | Hematologic Tests | 1 | 2019 | 22 | 0.660 |
Why?
| | Crotalus | 1 | 2019 | 18 | 0.650 |
Why?
| | Advanced Cardiac Life Support | 9 | 2022 | 23 | 0.650 |
Why?
| | Cocaine | 2 | 2012 | 153 | 0.640 |
Why?
| | Noninvasive Ventilation | 1 | 2019 | 32 | 0.620 |
Why?
| | Intubation, Intratracheal | 2 | 2019 | 215 | 0.600 |
Why?
| | Patient Outcome Assessment | 2 | 2017 | 122 | 0.590 |
Why?
| | Animals | 24 | 2020 | 31867 | 0.590 |
Why?
| | Physical Examination | 1 | 2019 | 221 | 0.590 |
Why?
| | Treatment Outcome | 21 | 2023 | 9122 | 0.590 |
Why?
| | Drug Hypersensitivity | 1 | 2018 | 85 | 0.580 |
Why?
| | Carbon Monoxide Poisoning | 3 | 2014 | 5 | 0.580 |
Why?
| | United States | 21 | 2023 | 12224 | 0.540 |
Why?
| | Adult | 29 | 2023 | 30655 | 0.520 |
Why?
| | Lithium Compounds | 1 | 2015 | 9 | 0.520 |
Why?
| | Drug Contamination | 2 | 2012 | 53 | 0.480 |
Why?
| | Renal Dialysis | 2 | 2015 | 369 | 0.470 |
Why?
| | Child | 24 | 2023 | 18407 | 0.470 |
Why?
| | Skin Diseases, Bacterial | 1 | 2014 | 22 | 0.460 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2014 | 39 | 0.460 |
Why?
| | Poisons | 1 | 2014 | 21 | 0.460 |
Why?
| | Prescription Drug Diversion | 1 | 2014 | 12 | 0.460 |
Why?
| | Soft Tissue Infections | 1 | 2014 | 30 | 0.460 |
Why?
| | Uncertainty | 1 | 2014 | 95 | 0.450 |
Why?
| | Narcotics | 1 | 2014 | 44 | 0.450 |
Why?
| | Hyperbaric Oxygenation | 2 | 2011 | 36 | 0.450 |
Why?
| | Indazoles | 1 | 2014 | 58 | 0.450 |
Why?
| | Cannabinoids | 1 | 2014 | 115 | 0.400 |
Why?
| | Serum Sickness | 1 | 2012 | 7 | 0.400 |
Why?
| | Antinematodal Agents | 1 | 2012 | 5 | 0.400 |
Why?
| | Young Adult | 12 | 2019 | 10498 | 0.400 |
Why?
| | Middle Aged | 18 | 2019 | 26827 | 0.390 |
Why?
| | Hypersensitivity, Immediate | 1 | 2012 | 46 | 0.390 |
Why?
| | Severity of Illness Index | 6 | 2019 | 2551 | 0.390 |
Why?
| | Anti-Infective Agents | 1 | 2014 | 225 | 0.390 |
Why?
| | Drug Design | 1 | 2012 | 151 | 0.380 |
Why?
| | Opioid-Related Disorders | 2 | 2019 | 414 | 0.380 |
Why?
| | False Negative Reactions | 1 | 2011 | 50 | 0.380 |
Why?
| | Acid-Base Equilibrium | 1 | 2011 | 30 | 0.380 |
Why?
| | Female | 27 | 2023 | 59611 | 0.370 |
Why?
| | Emergencies | 6 | 2020 | 147 | 0.370 |
Why?
| | Male | 24 | 2019 | 55730 | 0.370 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 87 | 0.360 |
Why?
| | Liver Failure | 1 | 2010 | 79 | 0.350 |
Why?
| | Premature Birth | 2 | 2023 | 278 | 0.350 |
Why?
| | Double-Blind Method | 3 | 2019 | 1664 | 0.350 |
Why?
| | Aged, 80 and over | 8 | 2019 | 6357 | 0.330 |
Why?
| | Common Cold | 1 | 2009 | 12 | 0.320 |
Why?
| | Antitussive Agents | 1 | 2009 | 8 | 0.320 |
Why?
| | First Aid | 6 | 2023 | 16 | 0.320 |
Why?
| | Hemorrhage | 1 | 2013 | 618 | 0.320 |
Why?
| | Aspirin | 1 | 2011 | 324 | 0.310 |
Why?
| | Acetylcysteine | 2 | 2010 | 142 | 0.310 |
Why?
| | Naloxone | 2 | 2020 | 97 | 0.290 |
Why?
| | Decision Support Techniques | 1 | 2011 | 351 | 0.290 |
Why?
| | Evidence-Based Medicine | 6 | 2020 | 676 | 0.290 |
Why?
| | Time Factors | 4 | 2019 | 6141 | 0.280 |
Why?
| | Infant | 12 | 2021 | 7945 | 0.280 |
Why?
| | Clinical Trials as Topic | 3 | 2023 | 937 | 0.280 |
Why?
| | Child, Preschool | 11 | 2020 | 9093 | 0.270 |
Why?
| | Follow-Up Studies | 5 | 2019 | 4420 | 0.260 |
Why?
| | Infant, Newborn | 10 | 2023 | 5040 | 0.260 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2019 | 1214 | 0.260 |
Why?
| | Adolescent | 11 | 2020 | 17862 | 0.260 |
Why?
| | Emergency Treatment | 3 | 2023 | 113 | 0.250 |
Why?
| | Practice Guidelines as Topic | 4 | 2021 | 1398 | 0.250 |
Why?
| | Aged | 10 | 2019 | 19119 | 0.230 |
Why?
| | Administration, Sublingual | 2 | 2014 | 13 | 0.230 |
Why?
| | Tablets | 2 | 2014 | 36 | 0.230 |
Why?
| | Digoxin | 1 | 2023 | 26 | 0.220 |
Why?
| | Algorithms | 1 | 2011 | 1488 | 0.220 |
Why?
| | Pediatrics | 2 | 2022 | 981 | 0.220 |
Why?
| | Risk Factors | 8 | 2021 | 8642 | 0.220 |
Why?
| | Liver | 1 | 2010 | 1681 | 0.210 |
Why?
| | Benzodiazepines | 1 | 2023 | 116 | 0.210 |
Why?
| | Disability Evaluation | 3 | 2023 | 271 | 0.200 |
Why?
| | International Classification of Functioning, Disability and Health | 1 | 2021 | 4 | 0.200 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2023 | 294 | 0.190 |
Why?
| | Asphyxia | 1 | 2020 | 21 | 0.180 |
Why?
| | Global Health | 1 | 2023 | 288 | 0.180 |
Why?
| | Fentanyl | 1 | 2020 | 65 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2017 | 1857 | 0.170 |
Why?
| | Incidence | 2 | 2018 | 2318 | 0.170 |
Why?
| | Blood Coagulation Disorders | 1 | 2002 | 195 | 0.170 |
Why?
| | Minimal Clinically Important Difference | 1 | 2019 | 10 | 0.160 |
Why?
| | Hypothermia, Induced | 1 | 2019 | 69 | 0.160 |
Why?
| | Observational Studies as Topic | 1 | 2019 | 90 | 0.160 |
Why?
| | Vasoconstrictor Agents | 2 | 2019 | 112 | 0.150 |
Why?
| | Airway Management | 1 | 2019 | 60 | 0.150 |
Why?
| | Comparative Effectiveness Research | 1 | 2019 | 130 | 0.150 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 250 | 0.150 |
Why?
| | Resuscitation | 1 | 2020 | 247 | 0.150 |
Why?
| | Early Medical Intervention | 1 | 2018 | 51 | 0.150 |
Why?
| | Prospective Studies | 3 | 2021 | 6232 | 0.150 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2020 | 231 | 0.150 |
Why?
| | Pregnancy Complications, Cardiovascular | 2 | 2015 | 64 | 0.150 |
Why?
| | Extracorporeal Circulation | 2 | 2019 | 14 | 0.150 |
Why?
| | ROC Curve | 1 | 2019 | 447 | 0.150 |
Why?
| | Interviews as Topic | 1 | 2019 | 584 | 0.140 |
Why?
| | Activities of Daily Living | 2 | 2021 | 351 | 0.140 |
Why?
| | Calcium | 1 | 2023 | 1104 | 0.140 |
Why?
| | Needs Assessment | 1 | 2019 | 316 | 0.140 |
Why?
| | Reproducibility of Results | 3 | 2019 | 2799 | 0.140 |
Why?
| | Heart | 1 | 2020 | 610 | 0.140 |
Why?
| | Calcium Channel Blockers | 1 | 2017 | 115 | 0.140 |
Why?
| | Quality of Life | 2 | 2019 | 2359 | 0.140 |
Why?
| | Fluoride Poisoning | 1 | 2016 | 4 | 0.130 |
Why?
| | Salicylates | 1 | 2016 | 30 | 0.130 |
Why?
| | Patient Care Team | 1 | 2020 | 515 | 0.130 |
Why?
| | Bupropion | 1 | 2016 | 39 | 0.130 |
Why?
| | Cysteine | 1 | 2017 | 171 | 0.130 |
Why?
| | Information Systems | 1 | 2016 | 61 | 0.130 |
Why?
| | Near Drowning | 1 | 2015 | 4 | 0.130 |
Why?
| | Cardiac Tamponade | 1 | 2015 | 14 | 0.130 |
Why?
| | Lithium Carbonate | 1 | 2015 | 6 | 0.130 |
Why?
| | Immunologic Factors | 2 | 2019 | 221 | 0.130 |
Why?
| | Age Factors | 2 | 2020 | 2894 | 0.130 |
Why?
| | Blood Proteins | 1 | 2017 | 233 | 0.130 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2017 | 125 | 0.130 |
Why?
| | Fat Emulsions, Intravenous | 1 | 2015 | 30 | 0.130 |
Why?
| | Water-Electrolyte Imbalance | 1 | 2015 | 26 | 0.130 |
Why?
| | Lead Poisoning, Nervous System, Adult | 1 | 2015 | 2 | 0.130 |
Why?
| | Psychometrics | 1 | 2019 | 608 | 0.130 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1080 | 0.130 |
Why?
| | Anaphylaxis | 2 | 2015 | 148 | 0.130 |
Why?
| | Hypothermia | 1 | 2015 | 39 | 0.120 |
Why?
| | Observer Variation | 1 | 2016 | 298 | 0.120 |
Why?
| | Ergotism | 1 | 2014 | 1 | 0.120 |
Why?
| | Ergotamine | 1 | 2014 | 2 | 0.120 |
Why?
| | Drama | 1 | 2014 | 2 | 0.120 |
Why?
| | Pain | 2 | 2019 | 709 | 0.120 |
Why?
| | Medicine in Literature | 1 | 2014 | 4 | 0.120 |
Why?
| | Literature, Modern | 1 | 2014 | 3 | 0.120 |
Why?
| | Wit and Humor as Topic | 1 | 2014 | 5 | 0.120 |
Why?
| | Muscle Weakness | 1 | 2015 | 80 | 0.120 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2014 | 18 | 0.120 |
Why?
| | Hypokalemia | 1 | 2014 | 25 | 0.120 |
Why?
| | Sex Factors | 1 | 2019 | 1721 | 0.120 |
Why?
| | Toxicology | 1 | 2014 | 36 | 0.110 |
Why?
| | Foreign Bodies | 1 | 2015 | 99 | 0.110 |
Why?
| | Opioid Peptides | 1 | 2013 | 4 | 0.110 |
Why?
| | Pharmacovigilance | 1 | 2013 | 14 | 0.110 |
Why?
| | Time-to-Treatment | 1 | 2015 | 147 | 0.110 |
Why?
| | Pulmonary Embolism | 1 | 2015 | 184 | 0.110 |
Why?
| | Housing | 1 | 2014 | 114 | 0.110 |
Why?
| | Drug Combinations | 1 | 2014 | 287 | 0.110 |
Why?
| | Crime | 1 | 2013 | 59 | 0.110 |
Why?
| | Statistics as Topic | 1 | 2014 | 298 | 0.110 |
Why?
| | Drug Packaging | 1 | 2013 | 43 | 0.110 |
Why?
| | Hypotension | 1 | 2014 | 114 | 0.110 |
Why?
| | Opiate Substitution Treatment | 1 | 2014 | 98 | 0.110 |
Why?
| | Costs and Cost Analysis | 1 | 2013 | 196 | 0.100 |
Why?
| | Retrospective Studies | 5 | 2015 | 12547 | 0.100 |
Why?
| | Half-Life | 1 | 2012 | 143 | 0.100 |
Why?
| | Wounds, Gunshot | 1 | 2015 | 188 | 0.100 |
Why?
| | Surveys and Questionnaires | 3 | 2023 | 4631 | 0.100 |
Why?
| | Universities | 1 | 2014 | 339 | 0.100 |
Why?
| | Central Nervous System | 1 | 2013 | 238 | 0.100 |
Why?
| | Databases, Factual | 1 | 2016 | 1132 | 0.090 |
Why?
| | Self Report | 1 | 2015 | 698 | 0.090 |
Why?
| | Evidence-Based Emergency Medicine | 1 | 2011 | 4 | 0.090 |
Why?
| | Disease Outbreaks | 1 | 2014 | 309 | 0.090 |
Why?
| | Phenotype | 1 | 2019 | 2815 | 0.090 |
Why?
| | Disease Models, Animal | 1 | 2020 | 3545 | 0.090 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 752 | 0.090 |
Why?
| | Regression Analysis | 1 | 2013 | 948 | 0.090 |
Why?
| | Crack Cocaine | 1 | 2010 | 8 | 0.090 |
Why?
| | Pilot Projects | 1 | 2015 | 1375 | 0.090 |
Why?
| | Leukopenia | 1 | 2010 | 27 | 0.090 |
Why?
| | Cross-Sectional Studies | 3 | 2017 | 4411 | 0.090 |
Why?
| | Liver Function Tests | 1 | 2010 | 106 | 0.090 |
Why?
| | Delphi Technique | 1 | 2011 | 163 | 0.090 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2015 | 445 | 0.090 |
Why?
| | Program Evaluation | 1 | 2014 | 825 | 0.090 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2011 | 129 | 0.090 |
Why?
| | Patient Selection | 1 | 2013 | 646 | 0.080 |
Why?
| | Leukocyte Count | 1 | 2010 | 292 | 0.080 |
Why?
| | Neutropenia | 1 | 2010 | 125 | 0.080 |
Why?
| | Cardiovascular Diseases | 1 | 2020 | 1729 | 0.080 |
Why?
| | Injections, Intravenous | 2 | 2010 | 202 | 0.080 |
Why?
| | Brain | 1 | 2020 | 2379 | 0.080 |
Why?
| | Risk | 1 | 2011 | 815 | 0.080 |
Why?
| | Bone Marrow | 1 | 2010 | 247 | 0.080 |
Why?
| | Pregnancy | 3 | 2015 | 5519 | 0.080 |
Why?
| | Administration, Oral | 1 | 2010 | 730 | 0.080 |
Why?
| | Pharmacy Service, Hospital | 1 | 2009 | 84 | 0.080 |
Why?
| | Wounds and Injuries | 1 | 2015 | 723 | 0.080 |
Why?
| | Respiration Disorders | 1 | 2009 | 68 | 0.080 |
Why?
| | Anti-Arrhythmia Agents | 2 | 2018 | 106 | 0.080 |
Why?
| | Nervous System Diseases | 1 | 2011 | 252 | 0.080 |
Why?
| | Disease Progression | 1 | 2015 | 2389 | 0.080 |
Why?
| | Congresses as Topic | 1 | 2009 | 198 | 0.080 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 242 | 0.080 |
Why?
| | Pregnancy Complications | 1 | 2012 | 430 | 0.080 |
Why?
| | Antidotes | 1 | 2009 | 135 | 0.070 |
Why?
| | Hypersensitivity | 1 | 2010 | 256 | 0.070 |
Why?
| | Respiration, Artificial | 3 | 2019 | 526 | 0.070 |
Why?
| | Registries | 1 | 2013 | 1763 | 0.060 |
Why?
| | Dosage Forms | 1 | 2005 | 10 | 0.060 |
Why?
| | Colorado | 1 | 2014 | 4089 | 0.060 |
Why?
| | Disease Management | 1 | 2008 | 563 | 0.060 |
Why?
| | Biomedical Research | 1 | 2009 | 585 | 0.060 |
Why?
| | Cooperative Behavior | 2 | 2020 | 383 | 0.060 |
Why?
| | Treatment Failure | 1 | 2004 | 332 | 0.050 |
Why?
| | Anesthesiologists | 1 | 2022 | 12 | 0.050 |
Why?
| | Air Ambulances | 1 | 2002 | 34 | 0.050 |
Why?
| | Fingers | 1 | 2002 | 83 | 0.050 |
Why?
| | Necrosis | 1 | 2002 | 210 | 0.050 |
Why?
| | Recurrence | 1 | 2004 | 941 | 0.050 |
Why?
| | Quality Assurance, Health Care | 2 | 2015 | 314 | 0.040 |
Why?
| | Ventilators, Mechanical | 2 | 2010 | 52 | 0.040 |
Why?
| | Bradycardia | 2 | 2010 | 48 | 0.040 |
Why?
| | North Carolina | 2 | 2014 | 97 | 0.040 |
Why?
| | Interdisciplinary Communication | 1 | 2020 | 185 | 0.040 |
Why?
| | Hyperthermia, Induced | 1 | 2019 | 65 | 0.040 |
Why?
| | Amiodarone | 1 | 2018 | 23 | 0.040 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2018 | 28 | 0.040 |
Why?
| | Lidocaine | 1 | 2018 | 41 | 0.040 |
Why?
| | Epinephrine | 1 | 2019 | 167 | 0.040 |
Why?
| | Monitoring, Physiologic | 2 | 2010 | 249 | 0.040 |
Why?
| | Magnesium | 1 | 2018 | 145 | 0.040 |
Why?
| | Critical Care | 1 | 2022 | 475 | 0.040 |
Why?
| | Advisory Committees | 1 | 2018 | 208 | 0.040 |
Why?
| | Atrial Fibrillation | 2 | 2010 | 325 | 0.030 |
Why?
| | Health Personnel | 1 | 2021 | 574 | 0.030 |
Why?
| | Systems Analysis | 1 | 2015 | 22 | 0.030 |
Why?
| | Reference Values | 1 | 2017 | 748 | 0.030 |
Why?
| | Blood Pressure | 1 | 2002 | 1539 | 0.030 |
Why?
| | Chelating Agents | 1 | 2015 | 65 | 0.030 |
Why?
| | Thailand | 1 | 2014 | 10 | 0.030 |
Why?
| | Orphan Drug Production | 1 | 2014 | 6 | 0.030 |
Why?
| | Thoracic Surgical Procedures | 1 | 2015 | 56 | 0.030 |
Why?
| | Biological Availability | 1 | 2014 | 119 | 0.030 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2014 | 63 | 0.030 |
Why?
| | Placebo Effect | 1 | 2014 | 51 | 0.030 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2014 | 62 | 0.030 |
Why?
| | Walking | 1 | 2017 | 424 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2014 | 172 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2014 | 285 | 0.030 |
Why?
| | Peripheral Vascular Diseases | 1 | 2014 | 98 | 0.030 |
Why?
| | Drug Interactions | 1 | 2014 | 347 | 0.030 |
Why?
| | Chorionic Gonadotropin, beta Subunit, Human | 1 | 2012 | 14 | 0.030 |
Why?
| | Hemoperfusion | 1 | 2012 | 4 | 0.030 |
Why?
| | Sorption Detoxification | 1 | 2012 | 3 | 0.030 |
Why?
| | Uterine Hemorrhage | 1 | 2012 | 34 | 0.030 |
Why?
| | Tissue and Organ Procurement | 1 | 2015 | 237 | 0.030 |
Why?
| | Pregnancy, Ectopic | 1 | 2012 | 52 | 0.030 |
Why?
| | Renal Replacement Therapy | 1 | 2012 | 66 | 0.020 |
Why?
| | Pelvis | 1 | 2012 | 90 | 0.020 |
Why?
| | International Cooperation | 1 | 2012 | 172 | 0.020 |
Why?
| | Data Collection | 1 | 2014 | 623 | 0.020 |
Why?
| | Abdominal Pain | 1 | 2012 | 135 | 0.020 |
Why?
| | Health Policy | 1 | 2014 | 333 | 0.020 |
Why?
| | Drug Administration Routes | 1 | 2010 | 40 | 0.020 |
Why?
| | Nausea | 1 | 2010 | 102 | 0.020 |
Why?
| | Public Health | 1 | 2014 | 435 | 0.020 |
Why?
| | Vomiting | 1 | 2010 | 124 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 372 | 0.020 |
Why?
| | Drug Storage | 1 | 2009 | 59 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 636 | 0.020 |
Why?
| | Research Design | 1 | 2014 | 930 | 0.020 |
Why?
| | Safety | 1 | 2010 | 297 | 0.020 |
Why?
| | Drug Utilization | 1 | 2009 | 167 | 0.020 |
Why?
| | Hospitalization | 1 | 2017 | 1754 | 0.020 |
Why?
| | Quality Improvement | 1 | 2015 | 953 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 3419 | 0.020 |
Why?
| | Societies, Medical | 1 | 2009 | 678 | 0.020 |
Why?
| | South Carolina | 1 | 2003 | 40 | 0.010 |
Why?
| | Debridement | 1 | 2003 | 74 | 0.010 |
Why?
| | Blood Transfusion | 1 | 2003 | 276 | 0.010 |
Why?
| | Obesity | 1 | 2010 | 2524 | 0.010 |
Why?
| | Hemodynamics | 1 | 2003 | 1017 | 0.010 |
Why?
| | Asthma | 1 | 2010 | 2051 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2003 | 1477 | 0.010 |
Why?
|
|
Lavonas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|